Adcimab 400mg Injection
Marketer
Adley Formulations
Salt Composition
Bevacizumab (400mg)
Overview Adcimab 400mg Injection
Oncaspar 400mg Injection, an anti-cancer agent, treats colorectal, non-small cell lung, kidney, brain, ovarian, and cervical cancers. Its mechanism involves inhibiting tumor angiogenesis, thus hindering tumor growth. Highly effective as a first-line treatment in combination therapy, it's administered intravenously via infusion or port. Dosage and treatment duration are determined by your physician, who will monitor for infusion reactions like hypertension and respiratory distress. Continued use depends on disease control and manageable side effects, as assessed by your doctor. Regular blood pressure monitoring and urine protein level checks may be advised. Common side effects include rectal hemorrhage, altered taste perception, and cephalalgia. Pre-surgical notification of Adcimab use is crucial due to its potential to impair wound healing. Increased bleeding risk necessitates immediate medical attention for any unusual bleeding. Disclose pregnancy, pregnancy plans, or breastfeeding to your physician. Inform your healthcare provider of all other medications you're taking, as drug interactions are possible.
Uses of Adcimab 400mg Injection
Colorectal cancer, ovarian neoplasm, cervical carcinoma, renal cell carcinoma, brain cancer, and non-small cell lung carcinoma.
Major Benefits of Adcimab 400mg Injection:
This medication will be administered by your physician or their qualified associate; please do not attempt self-medication.
Common Side effects of Adcimab 400mg Injection:
- Exfoliative dermatitis
- High blood pressure
- Nosebleeds
- Protein in urine
- Decreased appetite
- Electrolyte imbalance
- Peripheral sensory neuropathy
- Breathlessness
- Thromboembolism
- Wound healing complications
- Ovarian failure
- Decreased white blood cell count (lymphocytes)
- Low blood platelets
- Mucosal inflammation
- Abscess
- Cellulitis
- Hypersensitivity
- Rectovaginal fistula
How to use Adcimab 400mg Injection:
This medication will be administered by your healthcare provider; self-medication is strictly prohibited.
How Adcimab 400mg Injection works:
Adcimab 400mg Injection is an anti-angiogenesis agent. Its mechanism of action involves inhibiting vascular endothelial growth factor (VEGF), thereby preventing the development of new blood vessels supplying tumors with essential oxygen and nutrients.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Adcimab 400mg Injection may pose unknown risks. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
The use of Adcimab 400mg Injection during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the potential advantages against any possible risks prior to prescribing. Consult your doctor for advice.
Breast feedingCONSULT YOUR DOCTOR
The use of Adcimab 400mg Injection while breastfeeding is likely unsafe. Available human data indicates potential transfer of the medication into breast milk, posing a risk to the infant.
DrivingUNSAFE
Adcimab 400mg Injection can induce adverse reactions that might compromise driving capabilities. Drowsiness and loss of consciousness have been observed in patients receiving Adcimab 400mg Injection, potentially affecting driving safety.
KidneySAFE IF PRESCRIBED
Adcimab 400mg Injection appears to pose minimal risk for individuals with impaired renal function. Preliminary findings indicate that dose modification may be unnecessary in this population. Physician consultation is recommended.
LiverSAFE IF PRESCRIBED
Adcimab 400mg Injection appears to pose minimal risk for individuals with hepatic impairment. Preliminary findings indicate dose modification of Adcimab 400mg Injection may be unnecessary in this population. Physician consultation is recommended.
What if you forget to take Adcimab 400mg Injection :
Omit a dose of Adcimab 400mg Injection? Seek medical advice immediately.
Facts to Know About Adcimab 400mg Injection
| Label | Value |
|---|---|
| Chemical Type | Monoclonal antibody |
| Developing Good Habits | No. |
| Treatment Category | Cancer Medications |
| Action Class | VEGF-blocking agent |
3,018 People bought this recently